Group 1 - The company has revised its performance forecast for the fiscal year 2025, which spans from January 1, 2025, to December 31, 2025 [2][3] - The previous performance forecast indicated a decline in performance, as opposed to a turnaround or improvement [3] - The revision is based on the completion of employee performance evaluations, which revealed that some employees did not meet performance standards, necessitating a remeasurement of share-based payment expenses and year-end bonuses [4] Group 2 - The revised performance forecast is a preliminary estimate from the company's finance department and has not yet been audited by the accounting firm [5] - The company will provide detailed financial data in the 2025 annual report [5] - The board of directors has issued a statement regarding the performance forecast revision [6]

Core Viewpoint - Wanfu Biology (SZ300482) has revised its 2025 profit forecast from a profit of 46 million to 69 million yuan to a loss of 44.6 million to 67.6 million yuan due to a change in accounting treatment [1][3] Group 1: Financial Performance - The revised forecast indicates a year-on-year decline in net profit attributable to shareholders of 107.94% to 112.04%, compared to a profit of 562 million yuan in the same period last year [1][2] - The adjustment in accounting treatment involved recognizing approximately 113.6 million yuan of expenses related to a terminated equity incentive plan in the current period, leading to a significant drop in net profit [3] Group 2: Market and Industry Context - The IVD (in vitro diagnostics) industry is currently experiencing a downturn, with total revenue for the first three quarters of 2025 at 27.62 billion yuan, a year-on-year decrease of 14.5%, and net profit down 26.4% [4] - The company anticipates that 2025 will be a low point for both the industry and itself, but expects a rebound in 2026, describing the upcoming year as a period of "light load" and clearer growth trends [4][5] Group 3: Business Outlook - The company expects domestic business to experience a recovery, particularly in hospital-based operations, while overseas markets are projected to maintain healthy growth due to early expansion efforts [5] - New business initiatives, such as respiratory testing in the U.S., are expected to contribute to sustained growth in international markets [5]

Group 1 - One company has revised its performance forecast downward, while another company has adjusted its performance expectations [1] - The earnings forecast disclosure season is also a time when black swan events frequently occur, leading to downward revisions if actual performance falls below expectations [2] - According to statistics from Securities Times Data Treasure, a total of one company has downwardly revised its performance based on the median net profit growth rate [2] Group 2 - The company *ST亚太 has lowered its performance forecast range without changing the type of earnings forecast [2] - On the day of the announcement of downward performance revisions, the average stock price increased by 5.00%, and the average stock price has risen by 5.00% since the downward revision [2] - The latest performance forecast for *ST亚太 indicates a projected net loss of -69.61% compared to an initial forecast of -18.36% [2]

Core Viewpoint - ST Yushun (002289) has revised its 2024 annual performance forecast, now expecting a net loss of 19 million to 26.3 million yuan, compared to the previous estimate of a net loss of 15 million to 22.3 million yuan [1] Summary by Category - **Company Performance** - The company anticipates a larger net loss for 2024 than initially projected, indicating a downward revision in financial expectations [1] - The revised loss range reflects an increase in the expected financial shortfall, suggesting potential challenges in operational performance [1] - **Financial Forecast** - The new forecast estimates a net loss between 19 million and 26.3 million yuan, which is a significant adjustment from the earlier forecast of a loss between 15 million and 22.3 million yuan [1] - This adjustment highlights the company's ongoing financial difficulties and the need for strategic reassessment [1]

Core Viewpoint - Nanhua Biological (000504) has revised its 2024 annual performance forecast, now expecting a net loss of 19 million to 21 million yuan, a significant change from the previous forecast of a net profit of 12.5 million to 15.5 million yuan [1] Financial Performance - The company initially projected a net profit range of 12.5 million to 15.5 million yuan for 2024 [1] - The revised forecast indicates a potential loss of 19 million to 21 million yuan, reflecting a negative shift in financial expectations [1]

Core Viewpoint - The company, Jialinjie (002486), has revised its 2024 annual performance forecast, expecting a net profit of 15 million to 23 million yuan, significantly higher than the previous estimate of 4 million to 8 million yuan [1] Summary by Category - **Performance Forecast** - The revised net profit forecast is between 15 million yuan and 23 million yuan [1] - The original net profit estimate was between 4 million yuan and 8 million yuan [1]

Core Viewpoint - The company has revised its earnings forecast for the fiscal year 2024, indicating a positive net profit that is expected to increase compared to previous estimates [1][2]. Earnings Forecast - The earnings forecast period is from January 1, 2024, to December 31, 2024 [1]. - The previous earnings forecast, disclosed on January 25, 2025, indicated a positive net profit with an upward trend [1]. - The revised earnings forecast also anticipates a positive net profit and an upward trend [1]. Reasons for Earnings Revision - The company holds a 99.9969% stake in Changpei (Shanghai) Investment Center, which in turn holds 69,330.94 million shares of a certain Hong Kong-listed company [2]. - The Hong Kong-listed company reported significant losses that exceeded the company's prior expectations [2]. - The new product launches and market performance of existing products from the Hong Kong-listed company did not meet market expectations, prompting a reassessment of the long-term equity investment impairment losses [2]. Communication with Auditors - The company has communicated with its annual audit firm regarding the earnings forecast revision, confirming the adjustments after thorough discussions [1][2]. - There are no significant disagreements between the company and the audit firm regarding the revision, with final data to be based on the audit firm's verified financial data [1]. Additional Information - The company received an administrative penalty notice from the China Securities Regulatory Commission on April 1, 2024, and a formal penalty decision on November 6, 2024 [3]. - Following the penalty decision, the company has initiated a review of its financial reports and is in the process of correcting errors and making retrospective adjustments [3]. - The company expresses regret for any impact the earnings forecast revision may have on investors and commits to improving the quality of information disclosure [3].

Core Viewpoint - The company has revised its 2024 annual performance forecast, now expecting a negative net profit, which is a downward adjustment from the previous forecast of a positive net profit [1][2]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2024, to December 31, 2024 [1]. - The previous forecast indicated a positive net profit, but the revised forecast now anticipates a negative net profit [1]. Group 2: Reasons for Performance Revision - Interest capitalization: The company plans to expense interest amounting to 35.93 million yuan related to general borrowings used for the PBAT integration project [2]. - Transactional financial assets: The company holds equity in Beijing Jinse Century Travel Network Technology Co., Ltd., with a balance of 11.84 million yuan at the end of 2024. Due to unchanged operating conditions, the company intends to recognize fair value losses on this asset [3]. - Supply chain business: The company has long-aged accounts receivable/prepaid accounts totaling approximately 121.50 million yuan. Due to uncertainties in recovery, the company plans to reassess the recoverable amounts and make corresponding impairment provisions [4].

Performance Forecast - The company has revised its performance forecast for the fiscal year 2024, now expecting a net loss attributable to shareholders of between 500 million yuan and 750 million yuan, compared to the previous estimate of 300 million yuan to 450 million yuan [1][2] - The expected net loss after deducting non-recurring gains and losses has also been adjusted to between 521 million yuan and 771 million yuan, up from the earlier forecast of 321 million yuan to 471 million yuan [1][2] - The basic earnings per share is now projected to be a loss of 1.09 yuan to 1.63 yuan, compared to the previous estimate of a loss of 0.65 yuan to 0.98 yuan [1][2] Reasons for Revision - The revision is primarily due to long-term asset impairment issues at the company's subsidiary, Yangzhou Bangjie New Energy Technology Co., Ltd., exacerbated by the slower-than-expected recovery in the photovoltaic industry and further deterioration in the subsidiary's operating conditions [2][3] - The subsidiary is expected to temporarily cease operations starting March 2025, which has contributed to the increased impairment loss estimates [2][3] - The company has communicated with its annual audit accounting firm regarding the performance forecast and confirmed that there are no significant disagreements, with final data to be determined based on the audit results [2][3] Future Disclosure - The company will provide detailed financial data in its 2024 annual report, and the final asset impairment situation and specific amounts will be based on evaluations and audit results from the appointed assessment and audit institutions [3]